VAV Life Sciences unit to reach 40% of global mRNA lipid capacity next yr

Firm expanding mRNA lipids capacity 10-fold, overall plant capacity by 6 times by June

Mumbai-based firm VAV Life Sciences is expanding its mRNA lipids manufacturing capacity 10-fold by June 2022. It will then account for 40 percent of the total global capacity for m-RNA lipids, a critical component that goes into making mRNA vaccines and also various mRNA tech based therapeutic products which lends permeability and stability to the biologic product.

Apart from VAV, there are only three more companies in the world who make mRNA lipids. US-based Avanti Polar Lipids, Germany’s Lipoid and Japan’s NOF Corporation and VAV together now make 1,000 kg a year. However, the projected demand for mRNA lipids would